GPCR 250117 27.50P (GPCR250117P27500) Stock Options, News & Quotes - Moomoo

US OptionsDetailed Quotes

GPCR250117P27500

Watchlist

0.50
-0.63-55.75%

15min DelayClose Jan 17 16:00 ET

0.55High0.46Low

Intraday

5D
Daily

News

Can 2025 J.P. Morgan Healthcare Conference Spark Biotech M&A?
Seeking AlphaJan 11 15:06 ET
Stifel Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $50
Moomoo NewsJan 8 07:34 ET · Ratings
Stifel Initiates Structure Therapeutics(GPCR.US) With Buy Rating, Announces Target Price $50
Moomoo NewsJan 7 18:31 ET · Ratings
FDA Issues Draft Guidance on Developing Weight Loss Drugs
Seeking AlphaJan 7 11:53 ET
Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners For Weight Loss Products: Analyst
BenzingaJan 6 14:53 ET
SA Asks: Which Biotechs Are Most Likely to Be Acquired Near-term?
Seeking AlphaJan 5 17:32 ET

Comments

Dec 20, 2024 21:44

top line result Q4 2025

1

Sep 23, 2024 07:37

still uptrend..go buy target price $65

still uptrend..go buy target price $65

Share Your Profit/Loss

1

1

Sep 13, 2024 11:34

this one so hard to achieve 10% above. profit taken first.

Share Your Profit/Loss

3

1

Aug 13, 2024 09:44

$Structure Therapeutics (GPCR.US)$ hopefully the uptrend continues

Jul 17, 2024 22:40

Smid-cap obesity stocks hit by $RHHBY positive Ph1 data for oral GLP-1 obesity drug ⚠️

$ROCHE HOLDING AG (RHHBY.US)$
📣 Roche News Snippet:
» CT-996 led to significant weight loss (-7.3%) after 4 weeks 🆚 placebo (-1.2%)
» data supports once-daily oral dosing regimen
» Safety profile was similar to other GLP-1 drugs; no unexpected safety issues observed
Did you see today's sell-off? 🔴
$Eli Lilly and Co (LLY.US)$ $Novo-Nordisk A/S (NVO.US)$ $Structure Therapeutics (GPCR.US)$ $Viking Therapeutics (VKTX.US)$ $Lipocine (LPCN.US)$

Smid-cap obesity stocks hit by $RHHBY positive Ph1 data for oral GLP-1 obesity drug ⚠️

7

Read more